1R3 Stock Overview
Izotropic Corporation, a medical device company, develops and commercializes diagnostic products for detecting breast cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Izotropic Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.063 |
| 52 Week High | CA$0.27 |
| 52 Week Low | CA$0.051 |
| Beta | 2.03 |
| 1 Month Change | -10.57% |
| 3 Month Change | -21.75% |
| 1 Year Change | -69.61% |
| 3 Year Change | -90.66% |
| 5 Year Change | n/a |
| Change since IPO | -69.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1R3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -11.1% | -1.0% | 1.9% |
| 1Y | -69.6% | -5.0% | 4.6% |
Return vs Industry: 1R3 underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 1R3 underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| 1R3 volatility | |
|---|---|
| 1R3 Average Weekly Movement | 28.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1R3's share price has been volatile over the past 3 months.
Volatility Over Time: 1R3's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Bob Thast | izocorp.com |
Izotropic Corporation, a medical device company, develops and commercializes diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a 360-degree computed tomography imaging system designed for breast imaging. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Izotropic Corporation Fundamentals Summary
| 1R3 fundamental statistics | |
|---|---|
| Market cap | €4.48m |
| Earnings (TTM) | -€1.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs 1R3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1R3 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.82m |
| Earnings | -CA$2.82m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -52.0% |
How did 1R3 perform over the long term?
See historical performance and comparison